Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

November 30, 2027

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

BEBT-109 Capsules

BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.

DRUG

Pemetrexed Disodium for Injection

Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.

DRUG

Carboplatin Injection

Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.

DRUG

Cisplatin Injection

Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeBetter Med Inc

INDUSTRY